PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
about
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune CheckpointsThe effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune responsePredictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysisDevelopment of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung CancerImmunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesThe programmed death-1 immune-suppressive pathway: barrier to antitumor immunityHonokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell functionEmerging therapies for breast cancerTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.T cell coinhibition and immunotherapy in human breast cancerIn acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic moleculeT cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells.Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cellsPoxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancerPD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastasesPD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overviewGliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophagesB7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling.Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus.A New VISTA on combination therapy for negative checkpoint regulator blockade.PD-L1 expression in triple-negative breast cancer.Therapeutic targeting of B7-H1 in breast cancer.Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy.Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases.PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.Drug discovery in advanced prostate cancer: translating biology into therapy.Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
P2860
Q26738729-33847827-9757-46F1-9C62-02A7CD2A4FF7Q26766066-93869333-DFDE-4B65-95E7-FFD622B3AC72Q26769728-91193C5D-AF45-4B1C-AE73-4834C33ECC43Q26798047-DF59E531-2FE3-4816-B72D-1012C071CFACQ26798402-12E47848-0B3E-4339-9090-315E1691AE69Q26829847-BBB829D3-95F9-498E-A50E-230CF6BEB6A5Q28246944-86004BB8-3DD7-4F8D-A68B-0FC0174EC12CQ33617949-ABBC7CA0-3244-4843-A3D5-69223987DC57Q33769821-0E784F52-ADAC-410B-AA0B-0DBE311FA963Q33936154-DBDD469A-AFB0-4902-8742-4227EB8F9891Q34154994-08CE15D1-E6EF-40E3-B6E8-F9D9EC272CA5Q34173426-8FFC2373-C385-4DC8-B6E1-2F22B90B4934Q34577158-F50F04C9-2463-4FBD-B91B-84A10F8679A8Q35159355-50D6209D-7067-49CE-9A0F-046BF619B22AQ35623465-94A0F1B7-0700-400B-A5F0-B003BBC420D9Q35922960-2169C38E-7AD4-417D-AC7B-0DFD09FB880FQ35934137-40159A3C-D496-43D4-AFB3-77CECA66388BQ36269232-6C11BDC7-A5C5-4EF2-8A26-C2761B9C955EQ36303665-E9076682-B856-4A08-B943-BEB8F033C7C7Q36561681-C1FD0BC7-B337-4B59-B14D-99ADE5A5ED09Q36562180-737FD558-20BE-4554-9548-AC181017430DQ36567984-67579A64-DB9C-4D28-8B46-2972B241D24DQ36653524-7265BE08-3328-4B6A-8044-935B8F9EC2AEQ36806906-273116C4-ABB9-4DA7-9915-AF0EF0D32A2FQ37092938-46DAD565-C246-44C7-994E-3C53F68A44E2Q37348263-9112A94C-8BAC-4318-ACD6-2AEAC4F64AE1Q37422094-1DDDF168-0379-4EAF-B169-2334D961F2B9Q37462524-3F065445-047B-40A4-B727-F61CF3EAE02BQ37501853-509D8CC1-9466-4ACD-807C-ADFC0DABA6D3Q37517581-459C827D-9A6D-472A-9859-24D73EB53778Q37724790-612D5FB4-A259-4918-A83B-B79BE8C29726Q37922793-B86FE19C-9BF6-412B-AE5C-EDB31DE416FDQ37983730-BE373F97-9379-43F8-93F4-CA3251C3E22CQ38164258-23832A9D-EC98-480D-BC64-33D5F48C714BQ38389400-3196E287-23EA-458F-883A-E7BE1053A531Q38526844-2F94C701-A96B-4A4C-809A-D47FBF36191FQ38759770-4FA7C801-0303-453F-82DD-5C9A54C40AA2Q38824661-3AA57B3C-D572-4655-BA21-7C4A0072582DQ38839110-33753410-39CB-4DF5-BD48-A8C493747809Q38898344-AA3A8A42-EB76-497A-8168-A8292025A02C
P2860
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PI
@nl
PI(3) kinase is associated wit ...... in breast and prostate cancer
@en
type
label
PI
@nl
PI(3) kinase is associated wit ...... in breast and prostate cancer
@en
prefLabel
PI
@nl
PI(3) kinase is associated wit ...... in breast and prostate cancer
@en
P2093
P2860
P356
P1433
P1476
PI(3) kinase is associated wit ...... in breast and prostate cancer
@en
P2093
F M Waldman
J C Murray
R O Pieper
P2860
P2888
P304
P356
10.1038/ONC.2008.384
P407
P577
2008-10-13T00:00:00Z